Liver Disease News and Research

RSS

The liver is one of the largest solid organs of the body. It is located in the upper right part of the abdomen. Most of the organ lies under cover of the rib cage.

Body mass index found to mediate causal associations between Helicobacter pylori infections and coronary artery disease risk

Coronary heart disease (CHD) and H. Pylori.

23 Jan 2024

Study identifies genetic variants that influence response to preterm birth treatment

A UC San Francisco-led study has for the first time identified genetic variants that predict whether patients will respond to treatment for preterm birth, a condition that affects one in 10 infants born in the United States.

22 Jan 2024

Aerobic exercise could help combat non-alcoholic fatty liver disease

According to a study conducted on animal models and published in the journal Metabolism, aerobic exercise could help fight the non-alcoholic fatty liver disease, the most common liver disease worldwide: it affects nearly 24% of the global population and it usually causes a certain stigma among the affected people.

22 Jan 2024

Exploring the impact of probiotics on preventing weight gain from psychiatric medication

Researchers discuss the effectiveness of probiotics and their use in reducing drug-induced weight loss.

19 Jan 2024

Men with enlarged breast tissue may be at greater risk of early death

Men with enlarged breast tissue, not caused by excess weight—a condition formally known as gynecomastia—may be at heightened risk of an early death before the age of 75, suggests the first study of its kind, published online in the open access journal BMJ Open.

17 Jan 2024

TRPC3 emerges as key player in preventing damage from alcohol-associated liver disease

Excessive alcohol intake is strongly associated with alcohol-associated liver disease (ALD) which accounts for 25% and 30% of deaths from cirrhosis and hepatocellular carcinoma. Impairment of Ca2+ influx and Ca2+-mediated signaling in ALD suggests that Ca2+ channels are important in ALD pathological progression.

16 Jan 2024

Natural PLA2 inhibitor from marine fungus combats fatty liver disease by silencing lipotoxic pathways

This new article publication from Acta Pharmaceutica Sinica B, discusses the identification of a natural PLA2 inhibitor from the marine fungus Aspergillus sp. c1 for MAFLD treatment that suppressed lipotoxicity by inhibiting the IRE-1α/XBP-1s axis and JNK signaling.

16 Jan 2024

Exploring the link between pancreatic islet cell loss and age-related health conditions

Researchers from Tokyo Metropolitan University have studied pancreatic islet cell loss in people with no previous pancreatic problems. They identified key trends in the types of cells lost due to islet cell loss in different age groups and sexes, finding that ICL in the elderly population was largely due to insulin-producing beta cell loss.

13 Jan 2024

Groundbreaking study uncovers hundreds of genetic markers linked to insulin resistance

A genome-wide study of 402,398 individuals identifies 369 SNPs associated with insulin resistance, offering insights into metabolic diseases and potential therapeutic targets.

11 Jan 2024

Extended liver preservation technique shows promise for daytime transplants

Phase II clinical trial evaluates the safety and feasibility of prolonged DHOPE for extending human donor liver preservation to 20 hours, showing potential for facilitating daytime liver transplantation.

11 Jan 2024

New imaging technique could transform diagnosis and treatment of steatotic liver disease

Steatotic liver disease (SLD), previously known as non-alcoholic fatty liver disease, which includes a range of conditions caused by fat build-up in the liver due to abnormal lipid metabolism, affects about 25% of the population worldwide, making it the most common liver disorder.

9 Jan 2024

£30M clinical study will enhance the understanding of NASH cirrhosis

The most extensive clinical study into liver cirrhosis ever conducted worldwide has been announced by Newcastle University, University of Edinburgh and leading research-driven global biopharmaceutical company, Boehringer Ingelheim.

8 Jan 2024

Revolutionary study reveals Lactobacillus acidophilus could ward off liver cancer linked to fatty liver disease

Probiotic supplementation with Lactobacillus acidophilus could help prevent non-alcoholic fatty liver disease.

8 Jan 2024

Combining ezetimibe and bempedoic acid effectively lowers cholesterol in statin-intolerant patients

A simulation study analyzing over two million German outpatients found that combining ezetimibe and bempedoic acid effectively reduces LDL cholesterol in statin-intolerant patients with hypercholesterolemia.

7 Jan 2024

New app helps patients with alcohol-related liver disease recover, saves lives

A mobile phone app which helps patients with alcohol-related liver disease to stay sober could help save hundreds of lives every year, according to researchers from UCL and the Royal Free Hospital who developed the app.

5 Jan 2024

Gut microbes revealed as key players in liver disease solutions

In the editorial published on 4 September 2023, in the "gut-liver axis" special issue of the journal Hepatobiliary & Pancreatic Diseases International, Dr. Jian-Gao Fan and Dr. Lu Jiang from Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine provided a comprehensive elucidation of the pivotal role of gut microbiota in various liver diseases.

4 Jan 2024

CLivD score shows promise in early detection of steatotic liver disease and advanced fibrosis

Chronic liver disease, a growing threat to global health, often progresses silently in its early stages.

4 Jan 2024

Exploring the global health challenge of hepatitis D

Review explores the global impact of the hepatitis D virus (HDV) on public health, detailing its transmission, clinical course, diagnosis, and treatment options.

2 Jan 2024

New non-steroidal anti-inflammatory can inhibit the cytokine storm and preserve innate immunity

Very early in the COVID-19 pandemic clinical trials in patients hospitalized with COVID-19 confirmed that corticosteroids like dexamethasone reduced mortality, but they were harmful when applied at the first COVID-19 symptoms, due to the weakening of innate antiviral immunity, leading to delayed viral clearance and adverse outcomes in severe viral pneumonias.

28 Dec 2023

From diabetes drug to anti-inflammation powerhouse: The unexpected evolution of GLP-1

Research pioneer Dr. Daniel Drucker has much to be proud of, as the GLP-1-based diabetes drugs hailing from his early research are named 2023 breakthrough of the year by the Science Magazine.

18 Dec 2023